N/A
N=52
Application of Carbon Dioxide for Identifying the Intersegmental Plane in Thoracoscopic Segmentectomy
Lung Cancer · Pulmonary Nodule, Solitary · Segmentectomy · Pulmonary Nodule, Multiple
Bottom Line
View on ClinicalTrials.gov: NCT05350137 ↗Enrolled (actual)
52
Serious AEs
0.0%
Results posted
Feb 2024
Primary outcome: Primary: The Intersegmental Border Appearance Time During the Surgery. — 748.74; 157.11 seconds
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- 100% oxygen (Procedure); Carbon dioxide (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Tongji Hospital
- Primary completion
- Apr 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Intersegmental Border Appearance Time During the Surgery. |
748.74; 157.11 | — |
| SECONDARY The Arterial Blood Gas Results During Perioperative Period. |
— | — |
Summary
With the increasing acceptance of routine computed tomography (CT) screenings, early-stage lung cancer detection is becoming more frequent. For ground glass opacity predominant early-stage lung cancer, segmentectomy can get the same oncological benefits as lobectomy. In addition, lung nodules that are highly suspected to be metastases can also be performed by segmentectomy to preserve more lung function. During the surgery, the rapid and precise identification of the intersegmental plane is one of the challenges. The improved inflation-deflation method is currently the most widely used method in clinical practice. According to the dispersion coefficient of the gas, the rapid diffusion properties of carbon dioxide would be expected to speed lung collapse and so facilitate surgery. The purpose of this study was to investigate the feasibility and safety of carbon dioxide on the appearance time of satisfactory and ideal planes during segmentectomy.
Eligibility Criteria
Inclusion Criteria
- 18-80 years of age.
- Segmentectomy is feasible according to the reconstructed 3-dimensional (3D) images.
- Pulmonary nodule 2 cm or smaller in diameter with 50% or more ground-glass opacity (GGO) on thin-slice computed tomography, indicating an underlying malignancy.
- Ability to provide written informed consent.
- Unable to tolerate lobectomy as indicated by standard clinical pre-op evaluation, including pulmonary function tests and cardiac evaluation.
- Diagnosis confirmed or suspected of lung metastatic cancer.
Exclusion Criteria
- Patients who are at risk for general anesthesia.
- Patients with serious mental illness.
- Pregnancy or lactating women.
- Active bacterial or fungal infections.
- Panties with Interstitial pneumonia, pulmonary fibrosis or severe emphysema.
- Conversion to thoracotomy in surgery.
- Preoperative assessment of patients undergoing lobectomy.
Data sourced from ClinicalTrials.gov (NCT05350137). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.